Mirtazapine-associated rapid weight gain and decreased physical activity

Journal of Pharmacy Practice and Research

Volumn 34, Issue 4, 2004, Pages 308-309

  Kethini, Thejaswarup ^a,b   Alderman, Christopher P ^a,b   Doecke, Christopher J ^a,c  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b REPATRIATION GENERAL HOSPITAL   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR BLOCKING AGENT; HISTAMINE RECEPTOR; MIRTAZAPINE; SEROTONIN RECEPTOR; ZOPICLONE;

ADULT; APPETITE DISORDER; ARTICLE; BODY WEIGHT; BODY WEIGHT DISORDER; CASE REPORT; CAUCASIAN; DEPRESSION; DIETARY INTAKE; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; DRUG EFFECT; EXERCISE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LIPID BLOOD LEVEL; MALE; PATIENT MONITORING; PHYSICAL ACTIVITY; POSTTRAUMATIC STRESS DISORDER; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT; WEIGHT GAIN;

EID: 13544270883     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jppr2004344308     Document Type: Article

References (17)

1. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000; 355: 911-8.
2. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998; 51: 267-85.
3. Malhotra S, McElroy SL. Medical management of obesity associated with mental disorders. J Clin Psychiatry 2002; 63: 24-32.
4. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61: 37-41.
5. Abed RT, Cooper M. Mirtazapine causing hyperphagia. Br J Psychiatry 1999; 174: 181.
6. Carpenter LL, Leon Z, Yasmin S, Price LH. Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 1999; 11: 81-6.
7. Kraus T, Haack M, Schuld A, Hinze-Selch D, Koethe D, Pollmacher T. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 2002; 35: 220-5.
8. Goodnick PJ, Kremer C. Weight change during mirtazapine therapy. Prim Psychiatry 1998; 3: 103-8.
9. Kisfalen ME, Hsiung RC. Glucose dysregulation and mirtazapine-induced weight gain. Am J Psychiatry 2003; 160: 797.
10. Abraham G. Massive weight gain and hostility force mirtazapine stoppage. Can J Psychiatry 2002; 47: 582.
11. Blin O, Micallef J. Antipsychotic-associated weight gain and clinical outcome parameters. J Clin Psychiatry 2001; 62: 11-21.
12. Nicholas LM, Ford AL, Esposito SM, Ekstrom RD, Golden RN. The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry 2003; 64: 883-9.
13. Grundy MS, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-8.
14. Blackburn GL. Weight gain and antipsychotic medication. J Clin Psychiatry 2000; 61: 36-41.
15. Kosten TR, Ziedonis DM. Substance abuse and schizophrenia. Schizophr Bull 1997; 23: 181-6.
16. Tudor-Loeke CE, Bell RC, Myers AM, Harris SB, Lauzon N, Rodger NW. Pedometer-determined ambulatory activity in individuals with type 2 diabetes. Diabetes Res Clin Pract 2002; 55: 191-9.
17. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.